The	the	O	O
striatum	striatum	O	O
as	as	O	O
a	a	O	O
target	target	O	O
for	for	O	O
anti-rigor	anti-rigor	O	O
effects	effects	O	O
of	of	O	O
an	an	O	O
antagonist	antagonist	O	O
of	of	O	O
mGluR1	mglur1	O	O
,	,	O	O
but	but	O	O
not	not	O	O
an	an	O	O
agonist	agonist	O	O
of	of	O	O
group	group	B_chemicals	B_disease
II	ii	I_chemicals	I_disease
metabotropic	metabotropic	B_chemicals	O
glutamate	glutamate	B_chemicals	O
receptors	receptors	I_chemicals	O
.	.	O	O

The	the	O	O
aim	aim	O	O
of	of	O	O
the	the	O	O
present	present	O	O
study	study	O	O
was	was	O	O
to	to	O	O
find	find	O	O
out	out	O	O
whether	whether	O	O
the	the	O	O
metabotropic	metabotropic	S_chemicals	O
receptor	receptor	B_chemicals	O
1	1	I_chemicals	O
(	(	O	O
mGluR1	mglur1	O	O
)	)	O	O
and	and	O	O
group	group	B_chemicals	B_disease
II	ii	I_chemicals	I_disease
mGluRs	mglurs	O	O
,	,	O	O
localized	localized	O	O
in	in	O	O
the	the	O	O
striatum	striatum	O	O
,	,	O	O
are	are	O	O
involved	involved	O	O
in	in	O	O
antiparkinsonian-like	antiparkinsonian-like	O	O
effects	effects	O	O
in	in	O	O
rats	rats	O	O
.	.	O	O

Haloperidol	haloperidol	O	O
(	(	B_chemicals	O
1	1	I_chemicals	O
mg/kg	mg/kg	O	O
ip	ip	O	O
)	)	O	O
induced	induced	O	O
parkinsonian-like	parkinsonian-like	O	O
muscle	muscle	O	B_disease
rigidity	rigidity	O	I_disease
,	,	O	O
measured	measured	O	O
as	as	O	O
an	an	O	O
increased	increased	O	O
resistance	resistance	O	O
of	of	O	O
a	a	O	O
rat	rat	O	O
's	's	O	O
hind	hind	O	O
foot	foot	O	O
to	to	O	O
passive	passive	O	O
flexion	flexion	O	O
and	and	O	O
extension	extension	O	O
at	at	O	O
the	the	O	O
ankle	ankle	O	O
joint	joint	O	O
.	.	O	O

(RS)-1-aminoindan-1,5-dicarboxylic	(rs)-1-aminoindan-1,5-dicarboxylic	O	O
acid	acid	S_chemicals	O
(	(	O	O
AIDA	aida	O	O
;	;	O	O
0.5	0.5	O	O
-	-	O	O
15	15	O	O
microg/0.5	microg/0.5	O	O
microl	microl	O	O
)	)	O	O
,	,	O	O
a	a	O	O
potent	potent	O	O
and	and	O	O
selective	selective	O	O
mGluR1	mglur1	O	O
antagonist	antagonist	O	O
,	,	O	O
or	or	O	O
(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate	(2r,4r)-4-aminopyrrolidine-2,4-dicarboxylate	O	O
(	(	O	O
2R,4R-APDC	2r,4r-apdc	O	O
;	;	O	O
7.5	7.5	O	O
-	-	O	O
15	15	O	O
microg/0.5	microg/0.5	O	O
microl	microl	O	O
)	)	O	O
,	,	O	O
a	a	O	O
selective	selective	O	O
group	group	B_chemicals	B_disease
II	ii	I_chemicals	I_disease
agonist	agonist	O	O
,	,	O	O
was	was	O	O
injected	injected	O	O
bilaterally	bilaterally	O	O
into	into	O	O
the	the	O	O
striatum	striatum	O	O
of	of	O	O
haloperidol-treated	haloperidol-treated	O	O
animals	animals	O	O
.	.	O	O

AIDA	aida	O	O
in	in	O	O
doses	doses	O	O
of	of	O	O
7.5	7.5	O	O
-	-	O	O
15	15	O	O
microg/0.5	microg/0.5	O	O
microl	microl	O	O
diminished	diminished	O	O
the	the	O	O
haloperidol-induced	haloperidol-induced	O	O
muscle	muscle	O	B_disease
rigidity	rigidity	O	I_disease
.	.	O	O

In	in	O	O
contrast	contrast	O	O
,	,	O	O
2R,4R-APDC	2r,4r-apdc	O	O
injections	injections	O	O
were	were	O	O
ineffective	ineffective	O	O
.	.	O	O

The	the	O	O
present	present	O	O
results	results	O	O
may	may	O	O
suggest	suggest	O	O
that	that	O	O
the	the	O	O
blockade	blockade	O	O
of	of	O	O
striatal	striatal	O	O
mGluR1	mglur1	O	O
,	,	O	O
but	but	O	O
not	not	O	O
the	the	O	O
stimulation	stimulation	O	O
of	of	O	O
group	group	B_chemicals	B_disease
II	ii	I_chemicals	I_disease
mGluRs	mglurs	O	O
,	,	O	O
may	may	O	O
ameliorate	ameliorate	O	O
parkinsonian	parkinsonian	O	O
muscle	muscle	O	B_disease
rigidity	rigidity	O	I_disease
.	.	O	O

